This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Hypericin
Accession Number
DB13014
Type
Small Molecule
Groups
Investigational
Description

Hypericin is under investigation for the treatment of Cutaneous T-cell Lymphoma.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
7V2F1075HD
CAS number
548-04-9
Weight
Average: 504.4432
Monoisotopic: 504.084517488
Chemical Formula
C30H16O8
InChI Key
BTXNYTINYBABQR-UHFFFAOYSA-N
InChI
InChI=1S/C30H16O8/c1-7-3-9(31)19-23-15(7)16-8(2)4-10(32)20-24(16)28-26-18(12(34)6-14(36)22(26)30(20)38)17-11(33)5-13(35)21(29(19)37)25(17)27(23)28/h3-6,31-36H,1-2H3
IUPAC Name
5,7,11,18,22,24-hexahydroxy-13,16-dimethyloctacyclo[13.11.1.1²,¹⁰.0³,⁸.0⁴,²⁵.0¹⁹,²⁷.0²¹,²⁶.0¹⁴,²⁸]octacosa-1(27),2(28),3,5,7,10,12,14,16,18,21,23,25-tridecaene-9,20-dione
SMILES
CC1=CC(O)=C2C(=O)C3=C(O)C=C(O)C4=C3C3=C2C1=C1C(C)=CC(O)=C2C(=O)C5=C(O)C=C(O)C4=C5C3=C12

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UGlutathione S-transferase A1Not AvailableHuman
UGlutathione S-transferase PNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Hypericin.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Hypericin.Experimental
AmikacinThe risk or severity of adverse effects can be increased when Hypericin is combined with Amikacin.Approved, Investigational, Vet Approved
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Hypericin.Approved, Investigational, Withdrawn
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Hypericin is combined with Anthrax immune globulin human.Approved
Bacillus calmette-guerin substrain connaught live antigenThe risk or severity of adverse effects can be increased when Hypericin is combined with Bacillus calmette-guerin substrain connaught live antigen.Approved, Investigational
Bacillus calmette-guerin substrain tice live antigenThe risk or severity of adverse effects can be increased when Hypericin is combined with Bacillus calmette-guerin substrain tice live antigen.Approved
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Hypericin.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Hypericin is combined with Beclomethasone dipropionate.Approved, Investigational
BenzphetamineThe risk or severity of adverse effects can be increased when Hypericin is combined with Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Hypericin.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Hypericin.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Hypericin.Approved
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Hypericin.Approved
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Hypericin.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Hypericin.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Hypericin is combined with Carbamazepine.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Hypericin.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Hypericin.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Hypericin.Approved, Investigational
ClindamycinThe risk or severity of adverse effects can be increased when Hypericin is combined with Clindamycin.Approved, Vet Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Hypericin is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Hypericin.Approved, Illicit
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Hypericin is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Hypericin.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Hypericin.Approved, Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Hypericin.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Hypericin.Experimental
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Hypericin.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Hypericin.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Hypericin is combined with Desvenlafaxine.Approved, Investigational
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Hypericin.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Hypericin.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Hypericin.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Hypericin.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Hypericin.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Hypericin.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Hypericin.Approved, Investigational
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Hypericin.Approved, Investigational
DotarizineThe risk or severity of adverse effects can be increased when Hypericin is combined with Dotarizine.Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Hypericin.Approved, Vet Approved
EperisoneThe risk or severity of adverse effects can be increased when Hypericin is combined with Eperisone.Approved, Investigational
EthanolHypericin may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Hypericin.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Hypericin.Approved
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Hypericin.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Hypericin.Approved, Illicit, Investigational, Vet Approved
FingolimodHypericin may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Hypericin.Approved
FluoxetineThe risk or severity of adverse effects can be increased when Hypericin is combined with Fluoxetine.Approved, Vet Approved
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Hypericin.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Hypericin is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Hypericin is combined with Fluvoxamine.Approved, Investigational
G17DTThe risk or severity of adverse effects can be increased when Hypericin is combined with G17DT.Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Hypericin.Approved, Investigational
GemcitabineThe risk or severity of adverse effects can be increased when Gemcitabine is combined with Hypericin.Approved
GI-5005The risk or severity of adverse effects can be increased when Hypericin is combined with GI-5005.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Hypericin.Experimental
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Hypericin.Approved, Investigational
Hepatitis A VaccineThe risk or severity of adverse effects can be increased when Hypericin is combined with Hepatitis A Vaccine.Approved
Hepatitis B Vaccine (Recombinant)The risk or severity of adverse effects can be increased when Hypericin is combined with Hepatitis B Vaccine (Recombinant).Approved, Withdrawn
Human rabies virus immune globulinThe risk or severity of adverse effects can be increased when Hypericin is combined with Human rabies virus immune globulin.Approved
HydrocodoneHypericin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Hypericin.Approved, Vet Approved
Hydrocortisone acetateThe risk or severity of adverse effects can be increased when Hypericin is combined with Hydrocortisone acetate.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of adverse effects can be increased when Hypericin is combined with Hydrocortisone butyrate.Approved, Vet Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Hypericin.Approved
INGN 201The risk or severity of adverse effects can be increased when Hypericin is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Hypericin is combined with INGN 225.Investigational
IrinotecanThe risk or severity of adverse effects can be increased when Irinotecan is combined with Hypericin.Approved, Investigational
IsocarboxazidThe therapeutic efficacy of Hypericin can be increased when used in combination with Isocarboxazid.Approved
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Hypericin is combined with Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated).Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Hypericin.Approved, Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Hypericin.Experimental
LeflunomideThe risk or severity of adverse effects can be increased when Hypericin is combined with Leflunomide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Hypericin.Approved, Investigational
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Hypericin.Approved
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Hypericin.Approved, Investigational
Magnesium carbonateThe risk or severity of adverse effects can be increased when Hypericin is combined with Magnesium carbonate.Approved, Investigational
Magnesium citrateThe risk or severity of adverse effects can be increased when Hypericin is combined with Magnesium citrate.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Hypericin is combined with Magnesium hydroxide.Approved, Investigational
Magnesium sulfateThe therapeutic efficacy of Hypericin can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Hypericin is combined with Magnesium Trisilicate.Approved
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Hypericin.Approved
MethimazoleThe risk or severity of adverse effects can be increased when Hypericin is combined with Methimazole.Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Hypericin.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Hypericin.Approved, Vet Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Hypericin.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when Hypericin is combined with Natalizumab.Approved, Investigational
NeomycinThe risk or severity of adverse effects can be increased when Hypericin is combined with Neomycin.Approved, Vet Approved
OcrelizumabOcrelizumab may increase the immunosuppressive activities of Hypericin.Approved, Investigational
OleandrinOleandrin may decrease the cardiotoxic activities of Hypericin.Experimental, Investigational
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Hypericin.Approved
OuabainOuabain may decrease the cardiotoxic activities of Hypericin.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Hypericin.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Hypericin.Approved, Investigational, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Hypericin.Approved, Vet Approved
ParomomycinThe risk or severity of adverse effects can be increased when Hypericin is combined with Paromomycin.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Hypericin is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Hypericin.Experimental
PeruvosidePeruvoside may decrease the cardiotoxic activities of Hypericin.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Hypericin.Approved, Investigational
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Hypericin.Approved, Investigational
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Hypericin is combined with Polymyxin B Sulfate.Approved, Vet Approved
PramipexoleHypericin may increase the sedative activities of Pramipexole.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Hypericin.Approved, Vet Approved
PregabalinThe therapeutic efficacy of Hypericin can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Hypericin.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Hypericin.Approved, Investigational
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Hypericin.Experimental
PseudoephedrineThe risk or severity of adverse effects can be increased when Hypericin is combined with Pseudoephedrine.Approved
PyrantelThe risk or severity of adverse effects can be increased when Hypericin is combined with Pyrantel.Approved, Vet Approved
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Hypericin.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Hypericin is combined with Rabies virus inactivated antigen, A.Approved, Investigational
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Hypericin.Approved, Investigational
RindopepimutThe risk or severity of adverse effects can be increased when Hypericin is combined with Rindopepimut.Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Hypericin is combined with Rizatriptan.Approved
RoflumilastRoflumilast may increase the immunosuppressive activities of Hypericin.Approved
RopiniroleHypericin may increase the sedative activities of Ropinirole.Approved, Investigational
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Hypericin is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Hypericin is combined with Rubella virus vaccine.Approved, Investigational
Salmonella typhi ty2 vi polysaccharide antigenThe risk or severity of adverse effects can be increased when Hypericin is combined with Salmonella typhi ty2 vi polysaccharide antigen.Approved
Salmonella typhi Ty21a live antigenThe risk or severity of adverse effects can be increased when Hypericin is combined with Salmonella typhi ty21a live antigen.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Hypericin.Approved, Investigational
SRP 299The risk or severity of adverse effects can be increased when Hypericin is combined with SRP 299.Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Hypericin is combined with Sulfasalazine.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Hypericin is combined with Sumatriptan.Approved, Investigational
TacrolimusTacrolimus may increase the immunosuppressive activities of Hypericin.Approved, Investigational
TecemotideThe risk or severity of adverse effects can be increased when Hypericin is combined with Tecemotide.Investigational
TetracyclineThe risk or severity of adverse effects can be increased when Hypericin is combined with Tetracycline.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Hypericin.Investigational
TetrandrineThe risk or severity of adverse effects can be increased when Hypericin is combined with Tetrandrine.Experimental
TG4010The risk or severity of adverse effects can be increased when Hypericin is combined with TG4010.Investigational
TofacitinibHypericin may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Hypericin.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Hypericin.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Hypericin.Approved, Investigational
TrimethadioneThe risk or severity of adverse effects can be increased when Hypericin is combined with Trimethadione.Approved
Typhoid VaccineThe risk or severity of adverse effects can be increased when Hypericin is combined with Typhoid Vaccine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Hypericin.Approved, Investigational
VancomycinThe risk or severity of adverse effects can be increased when Hypericin is combined with Vancomycin.Approved
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of adverse effects can be increased when Hypericin is combined with Varicella Zoster Vaccine (Live/Attenuated).Approved
VecuroniumThe risk or severity of adverse effects can be increased when Hypericin is combined with Vecuronium.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Hypericin.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Hypericin is combined with Venlafaxine.Approved
VinpocetineThe risk or severity of adverse effects can be increased when Hypericin is combined with Vinpocetine.Investigational
Yellow Fever VaccineThe risk or severity of adverse effects can be increased when Hypericin is combined with Yellow Fever Vaccine.Approved, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Hypericin.Approved
ZidovudineThe risk or severity of adverse effects can be increased when Hypericin is combined with Zidovudine.Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Hypericin is combined with Zolmitriptan.Approved, Investigational
ZolpidemHypericin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Hypericin.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0034271
KEGG Compound
C07606
PubChem Compound
5281051
PubChem Substance
347829150
ChemSpider
4444511
BindingDB
50060874
ChEBI
5835
ChEMBL
CHEMBL286494
Wikipedia
Hypericin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections2
3RecruitingTreatmentCutaneous T-Cell Lymphoma (CTCL)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00732 mg/mLALOGPS
logP3.92ALOGPS
logP7.7ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)1.39ChemAxon
pKa (Strongest Basic)16.11ChemAxon
Physiological Charge-4ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area155.52 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity139.31 m3·mol-1ChemAxon
Polarizability50.96 Å3ChemAxon
Number of Rings8ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , negativeLC-MS/MSsplash10-0udi-0000090000-e9cd20b64eba34b7fb1e
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-0000590000-d6f4544a5f160b2a5b67

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzopyrenes. These are organic compounds containing a benzene fused to a pyrene(benzo[def]phenanthrene) ring system.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Pyrenes
Sub Class
Benzopyrenes
Direct Parent
Benzopyrenes
Alternative Parents
Phenanthro-perylenequinones / Triphenylenes / Chrysenes / Phenanthrols / Anthracenes / Naphthols and derivatives / 1-hydroxy-2-unsubstituted benzenoids / Vinylogous acids / Polyols / Organic oxides
show 1 more
Substituents
Benzo-a-pyrene / Benzo-e-pyrene / Phenanthro-perylenequinone / Perylenequinone / Chrysene / Triphenylene / Phenanthrol / Phenanthrene / Anthracene / 1-naphthol
show 9 more
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
carbopolycyclic compound (CHEBI:5835) / Anthracenes and phenanthrenes, Anthrone type (C07606) / Anthracenes and phenanthrenes (LMPK13040001)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Glutathione transferase activity
Specific Function
Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles.
Gene Name
GSTA1
Uniprot ID
P08263
Uniprot Name
Glutathione S-transferase A1
Molecular Weight
25630.785 Da
References
  1. Lu WD, Atkins WM: A novel antioxidant role for ligandin behavior of glutathione S-transferases: attenuation of the photodynamic effects of hypericin. Biochemistry. 2004 Oct 12;43(40):12761-9. [PubMed:15461448]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
S-nitrosoglutathione binding
Specific Function
Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. Regulates negatively CDK5 activity via p25/p35 translocation to prevent neurodegeneration.
Gene Name
GSTP1
Uniprot ID
P09211
Uniprot Name
Glutathione S-transferase P
Molecular Weight
23355.625 Da
References
  1. Lu WD, Atkins WM: A novel antioxidant role for ligandin behavior of glutathione S-transferases: attenuation of the photodynamic effects of hypericin. Biochemistry. 2004 Oct 12;43(40):12761-9. [PubMed:15461448]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Lu WD, Atkins WM: A novel antioxidant role for ligandin behavior of glutathione S-transferases: attenuation of the photodynamic effects of hypericin. Biochemistry. 2004 Oct 12;43(40):12761-9. [PubMed:15461448]

Drug created on October 20, 2016 20:05 / Updated on August 02, 2018 06:46